» Articles » PMID: 35862507

Comprehensive Narrative Review of Real-world COVID-19 Vaccines: Viewpoints and Opportunities

Overview
Journal Med Rev (2021)
Publisher De Gruyter
Specialty General Medicine
Date 2022 Jul 21
PMID 35862507
Authors
Affiliations
Soon will be listed here.
Abstract

Currently, people all over the world have been affected by coronavirus disease 2019 (COVID-19). Fighting against COVID-19 is the top priority for all the countries and nations. The development of a safe and effective COVID-19 vaccine is considered the optimal way of ending the pandemic. Three hundred and 44 vaccines were in development, with 149 undergoing clinical research and 35 authorized for emergency use as to March 15 of 2022. Many studies have shown the effective role of COVID-19 vaccines in preventing SARS-CoV-2 infections as well as serious and fatal COVID-19 cases. However, tough challenges have arisen regarding COVID-19 vaccines, including long-term immunity, emerging COVID-19 variants, and vaccine inequalities. A systematic review was performed of recent COVID-19 vaccine studies, with a focus on vaccine type, efficacy and effectiveness, and protection against SARS-CoV-2 variants, breakthrough infections, safety, deployment and vaccine strategies used in the real-world. Ultimately, there is a need to establish a unified evaluation standard of vaccine effectiveness, monitor vaccine safety and effectiveness, along with the virological characteristics of SARS-CoV-2 variants; and determine the most useful booster schedule. These aspects must be coordinated to ensure timely responses to beneficial or detrimental situations. In the future, global efforts should be directed toward effective and immediate vaccine allocations, improving vaccine coverage, SARS-CoV-2 new variants tracking, and vaccine booster development.

Citing Articles

Characteristics and Outcomes for Recipients of NVX-CoV2373: A Real-World Retrospective Study in Germany.

Kutikova L, Brash J, Helme K, Brewster J, Brand M, Adam A Vaccines (Basel). 2024; 12(4).

PMID: 38675769 PMC: 11054037. DOI: 10.3390/vaccines12040387.


BA.1/BA.5 Immunogenicity, Reactogenicity, and Disease Activity after COVID-19 Vaccination in Patients with ANCA-Associated Vasculitis: A Prospective Observational Cohort Study.

Speer C, Tollner M, Benning L, Bartenschlager M, Kim H, Nusshag C Viruses. 2023; 15(8).

PMID: 37632120 PMC: 10458303. DOI: 10.3390/v15081778.


A Review of Inactivated COVID-19 Vaccine Development in China: Focusing on Safety and Efficacy in Special Populations.

Hu L, Sun J, Wang Y, Tan D, Cao Z, Gao L Vaccines (Basel). 2023; 11(6).

PMID: 37376434 PMC: 10302808. DOI: 10.3390/vaccines11061045.


Serological Response to SARS-CoV-2 after COVID-19 Vaccination in Lung Cancer Patients: Short Review.

Rodilla A, Tavolacci S, Cagan J, Shah T, Mittan S, Mack P Vaccines (Basel). 2023; 11(5).

PMID: 37243073 PMC: 10223259. DOI: 10.3390/vaccines11050969.

References
1.
Baden L, El Sahly H, Essink B, Kotloff K, Frey S, Novak R . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; 384(5):403-416. PMC: 7787219. DOI: 10.1056/NEJMoa2035389. View

2.
Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View

3.
Hillus D, Schwarz T, Tober-Lau P, Vanshylla K, Hastor H, Thibeault C . Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respir Med. 2021; 9(11):1255-1265. PMC: 8360702. DOI: 10.1016/S2213-2600(21)00357-X. View

4.
Tenforde M, Olson S, Self W, Talbot H, Lindsell C, Steingrub J . Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years - United States, January-March 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(18):674-679. PMC: 9368749. DOI: 10.15585/mmwr.mm7018e1. View

5.
Blachere N, Hacisuleyman E, Darnell R . Vaccine Breakthrough Infections with SARS-CoV-2 Variants. Reply. N Engl J Med. 2021; 385(2):e7. DOI: 10.1056/NEJMc2107808. View